NCT04073680: An overdue trial by Petra Pharma
This trial is overdue. It was due to report 3 years, 4 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT04073680 |
|---|---|
| Title | A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors With PIK3CA or KRAS Mutations |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 1, 2020 |
| Completion date | July 15, 2021 |
| Required reporting date | July 15, 2022, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 25, 2025 |
| Days late | 1229 |